A phase II Study of Decitabine and Gemtuzumab Ozogamicin in Newly Diagnosed and Relapsed Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome

BACKGROUND: Decitabine may open the chromatin structure of leukemia cells making them accessible to the calicheamicin epitope of gemtuzumab ozogamicin (GO). METHODS: 110 patients (median age 70 years; range 27–89 years) were treated with decitabine and GO in a trial designed on model based futility...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Leukemia
Hauptverfasser: Daver, Naval, Kantarjian, Hagop, Ravandi, Farhad, Estey, Elihu, Wang, Xuemei, Garcia-Manero, Guillermo, Jabbour, Elias, Konopleva, Marina, O’Brien, Susan, Verstovsek, Srdan, Kadia, Tapan, Dinardo, Courtney, Pierce, Sherry, Huang, Xuelin, Pemmaraju, Naveen, Diaz-Pines-Mateo, Maria, Cortes, Jorge, Borthakur, Gautam
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2015
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4790089/
https://ncbi.nlm.nih.gov/pubmed/26365212
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2015.244
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge